Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Apr. 2 announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $8.56 moved to $8.72 on last trade day and at the end of the day closed at $8.06. Company price to sales ratio in past twelve months was calculated as 32.93 and price to cash ratio as 6.33. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive weekly performance of 5.08%.
This is a strong week for Seattle Genetics, Inc. (NASDAQ:SGEN). The company’s rating climbs to B from the previous week’s C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Seattle Genetics, Inc. (NASDAQ:SGEN) shares fell -6.16% in last trading session and ended the day on $43.91. SGEN return on equity ratio is recorded as -26.80% and its return on assets is -13.20%. Seattle Genetics, Inc. (NASDAQ:SGEN) yearly performance is 29.03%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Total 2013 revenues decreased to $17.3 million as compared to 2012 revenues of $26.3 million. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved down -5.32% in last trading session and was closed at $10.32, while trading in range of $10.23 – $10.99. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) year to date (YTD) performance is 35.79%.
Aegerion Pharmaceuticals (NASDAQ:AEGR) Insider Craig Fraser sold 2,250 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $46.20, for a total transaction of $103,950.00. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) weekly performance is -1.38%. On last trading day company shares ended up $44.39. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) distance from 50-day simple moving average (SMA50) is -21.45%. Analysts mean target price for the company is $98.20.
Leave a Reply